SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is facing significant downward pressure following an earnings report that highlighted a weak outlook and slower-than-expected turnaround in the China market, triggering a wave of analyst downgrades. Community discussion is heavily polarized between investors betting on a long-term 'buy the dip' opportunity for an iconic brand and those warning of a structural decline due to increased competition and shifting consumer preferences.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is attracting heavy investor attention as the company moves its earnings report to April 1st, fueling speculation about a potential surprise and the upcoming impact of U.S. federal cannabis rescheduling. While bulls are pointing to recent beverage partnerships and potential growth in the CBD pilot program as key catalysts for a rally, bearish participants remain focused on concerns regarding share dilution and the company's management track record.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly (LLY) is trending following an FDA warning against telehealth companies for misleading marketing of compounded GLP-1 medications, a move that clarifies market expectations and increases regulatory scrutiny on the weight-loss drug space. The community is actively debating the stock's valuation, the long-term impact of potential pricing pressures, and the highly anticipated upcoming FDA approval for the company's oral obesity pill, orforglipron.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is seeing intense market volatility and debate following a mixed earnings report that missed profit estimates, with investors weighing the company's long-term global expansion plans against ongoing headwinds from the challenging housing market and complex tariff impacts. The community remains deeply divided, with some traders hunting for a short-term squeeze or long-term value entry, while others express skepticism over the company's high debt levels and luxury furniture demand in the current economic climate.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing intense speculative momentum as investors closely monitor reports of a potential acquisition, with SpaceX and Amazon frequently cited as the primary parties vying for the company's critical satellite spectrum. The community is actively debating the timing of an official announcement, particularly as Globalstar approaches a scheduled earnings call and industry observers look for signs of a strategic move to secure the company's direct-to-device infrastructure.

Mega Fortune Co., Ltd. operates as a holding company which provides information technology services. It specializes in delivering comprehensive IoT solutions and services across various industries. The firm offers low carbon property management, energy, stock and GreenTech management services. The company was founded in 2011 and is headquartered in Hong Kong.

Mega Fortune Co Ltd.

Mega Fortune Company Limited

Mega Fortune Company Limited is generating significant trading volume as traders speculate on its potential for volatile price swings common among low-float Chinese IPOs. The community is actively debating whether the stock will mirror historical patterns of massive short-term surges or succumb to typical pump-and-dump mechanics, with many monitoring its low float and share lock-up status.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is seeing heightened activity driven by its reputation as a volatile, low-float runner, with investors intensely debating whether it will repeat past parabolic short squeezes. Community discussions are heavily split between those betting on another massive upside move fueled by tight share availability and those warning of the risks inherent in the stock's speculative, pump-and-dump nature.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors digest the commercial launch of Yartemlea and monitor the potential for near-term milestone payments from its multi-billion dollar partnership with Novo Nordisk. Community discussion remains heavily focused on the stock's significant short interest, with many retail shareholders expressing frustration over stagnant price action while others remain bullish on the long-term value of the company's pipeline and pending European regulatory developments.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as the company receives FDA approval for a higher-dose version of Wegovy, a move aimed at boosting efficacy and strengthening its competitive standing in the GLP-1 weight-loss market. The community is actively debating the stock's long-term potential, with bulls pointing to the new FDA milestone and a robust pipeline, while others remain skeptical due to pricing pressures, intense competition from Eli Lilly, and recent volatility in the broader pharmaceutical sector.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is trending following the announcement of a massive multi-year AI infrastructure contract, fueling intense community speculation about its low-float potential to trigger a significant short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Global Health Publishes Postal Ballot Voting Results and Scrutinizer’s Report

Global Health Limited ( ($IN:MEDANTA) ) has provided an announcement. Global Health Limited, the operator of Medanta hospitals, is a listed Indian ...

Medanta Ranked India’s Best Hospital by Newsweek

• Named No. 1 in the country in list of ‘World’s Best Hospitals 2026’ • Among top global healthcare institutions for the seventh year running Gurugram, Haryana, India – Business Wire India Medanta – The Medicity, Gurugram, operated by Global Health Limited, has been ranked the No. 1 hospital in India in Newsweek’s prestigious ‘World’s […]

Cardiac care at a new era: Medanta showcases future of advanced heart treatment

Guwahati, January 28 : Cardiovascular diseases (CVDs) are a major and growing public health concern in Assam and have emerged as one of the leading causes of death in adults above the age of 40 years. Further, studies have indicated that people living in urban areas, including hilly regions, are increasingly vulnerable to CVDs, often well before they turn 40. Gurgaon-based Medanta - The Medicity, named the Best Private Hospital in India by Newsweek for six years in a row, leads the way in clinical research and advanced treatment options for a wide range of cardiac diseases, including Coronary Artery Disease (CAD) and Valvular Heart Disease (VHD). In a continued effort to improve medical care in the Northeastern states, Medanta brought its specialized expertise to Guwahati, with Dr. Praveen Chandra, Chairman, Interventional Cardiology, Cardiac Care at Medanta. The Medicity emphasizes the urgent need for early detection and management of advanced cardiac conditions. He further underscored Medanta's commitment to making world-class healthcare accessible to patients across the country.

Brief Healthcare: Primer: HeXun Biosciences (6986 TT) - Nov 2025 and more

In this briefing: Primer: HeXun Biosciences (6986 TT) - Nov 2025 Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch 1. Primer: HeXun Biosciences (6986 TT) - Nov 2025 HeXun Biosciences operates a unique and synergistic dual-strategy business model, leveraging stable cash flow from its Contract Development and Manufacturing Organization (CDMO) services to fund its in-house development of high-potential stem cell-based new drugs. The company is strategically positioned in the high-growth regenerative medicine and biologics markets, with a focus on mesenchymal stem cells (MSCs) for cardiovascular diseases, a leading cause of death globally. Recent financial performance demonstrates exceptional growth, with revenue increasing by 119.36% and net income by 339.62% in the most recent fiscal year, transitioning the company from a loss-making entity to a profitable one with strong margin expansion.

Brief Healthcare: Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook and more

In this briefing: Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch Primer: Classys (214150 KS) - Nov 2025 1. Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook For 3Q25, Classys reported in-line revenue of W83bn (+40% YoY) and below-consensus operating profit of W37.6bn (+30% YoY; OP margin of 45.3%). By category, aesthetic device revenue grew 30% YoY to W42.9bn, consumables revenue expanded 46% YoY to W37.3bn, and other revenue surged 310% YoY to W2.7bn. By region, domestic revenue climbed 57% YoY to W29.8bn, and overseas revenue increased 32% YoY to W53bn. Excluding Brazil, overseas revenue expanded 80% YoY. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Healthcare: Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... and more

In this briefing: Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch Primer: Classys (214150 KS) - Nov 2025 Canbas Co Ltd (4575 JP): Q1 FY 06/26 flash update 1. Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Revenue In Line; Profitability Impacted by New Units: KIMS reported revenue broadly in line with our estimates, while EBITDA and PAT came in below expectations due to the initial ramp-up of new hospitals and the resultant operating deleverage. Profitability was impacted by higher depreciation and interest costs associated with the new facilities introduced. Reported revenue stood at 961 Cr, with margins at 21.2%, impacted by the addition of new units. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Equities Bottom-Up: VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY and more

In this briefing: VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch 1. VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY Robust Execution and Order Pipeline to Fuel H2FY26 Growth: Wabag delivered a 19% YoY growth in revenue for Q2FY26, broadly meeting our estimates. Revenue recognition is typically skewed towards the second half of the year, indicating strong H2. The management mentioned that margins may vary on a quarterly basis, while the medium-term margin outlook remains intact. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Growth Ideas: VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY and more

Brief Equities Bottom-Up: KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 and more

In this briefing: KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch Calix’s Next Frontier: Can MDUs & International Push Boost Its Market Performance? 1. KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 Macro Environment Outlook: The overall macro environment has shown a marked improvement, with uncertainty levels reducing by over 50% compared to Q4FY25. Europe displayed strong traction during the quarter as clients began transitioning their supply chains from local to more globally integrated ecosystems. Deal Wins/Pipeline: The company announced a major multi-year, multi-domain deal from a leading European OEM. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Growth Ideas: Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI and more

In this briefing: Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch HPG [BUY +38.0%] - Local, Global Tailwinds Support Solid Outlook VCB [BUY +25.3%] - EPS Growth to Improve in 2026-27; Attractive Valuation 1. Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI Strong Operating Metrics: EOP REIT’s revenue rose 13% YoY to Rs 1,124 Cr, supported by portfolio expansion, strong leasing, and rent escalations. Total office space expanded 7% YoY to 40.9 Mn sq. ft., with new additions at Embassy Tech Village and Embassy Manyata. Healthy pre-leasing levels (97–100%) and lower vacancies lifted occupancy by 300 bps YoY to 90%. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below. 2. Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Uptick in Revenue and Profitability: Revenue, EBITDA, and Adjusted PAT increased by 9.1%, 25.7%, and 29.2% YoY, respectively, driven by strong demand in API, especially in the export market, leading to overall volume growth of 9% and negative variance of ~2%.

Global Health Ltd. engages in the provision of healthcare, pathology, and other medical services. It engages in the research and development activities related to drugs, surgery, medical devices and equipment. The company was founded on August 13, 2004 and is headquartered in Gurugram, India.

Current Price	986.65
Prev Close	964.00
Open	976.15
Dividend Yield	0.04%
50-Day Moving Average	1,089.80
Beta	-0.07
Avg. Volume	204,668.53
PE Ratio	51.71

52-Week High	1,456.50
52-Week Low	956.00
Market Capitalization	258.51B
EPS (Annual)	17.92
Price to Book	7.17
Revenue Per Employee	2.98M

MEDANTA.NSE
Global Health Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest MEDANTA.NSE News

MEDANTA.NSEGlobal Health Ltd.